Get the Stockscreener App
4.82
3.98%
-0.20
After Hours:
4.79
-0.03
-0.62%
Dogwood Therapeutics Inc stock is traded at $4.82, with a volume of 105.87K.
It is down -3.98% in the last 24 hours and up +13.41% over the past month.
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$5.02
Open:
$4.98
24h Volume:
105.87K
Relative Volume:
0.06
Market Cap:
$10.68M
Revenue:
-
Net Income/Loss:
$-5.73M
P/E Ratio:
-0.7359
EPS:
-6.55
Net Cash Flow:
$-4.13M
1W Performance:
-13.77%
1M Performance:
+13.41%
6M Performance:
+4.33%
1Y Performance:
+0.00%
1-Day Range:
$4.76
$5.20
1-Week Range:
$4.76
$5.71
52-Week Range:
$1.62
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
4.82 | 10.68M | 0 | -5.73M | -4.13M | -6.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Dogwood Therapeutics Inc expected to post a loss of $2.37 a shareEarnings Preview - TradingView
Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
Exclusive Access: Dogwood Therapeutics CEO Hosts Private Investor Meetings at Prestigious NYC Conference - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Upgraded at HC Wainwright - Defense World
HC Wainwright & Co. Upgrades Dogwood Therapeutics (DWTX) - Nasdaq
HC Wainwright Upgrades Dogwood Therapeutics to Buy From Neutral - marketscreener.com
Financial Metrics Unveiled: Dogwood Therapeutics Inc (DWTX)’s Key Ratios in the Spotlight - DWinneX
Best Biotech Stocks To Watch Today – April 21st - Defense World
Dogwood Therapeutics Inc (NASDAQ: DWTX) Has Been Trading Down. What Are The Prospects For The Future? - Stocksregister
You might want to take a look at Dogwood Therapeutics Inc (DWTX) now - Sete News
You Should Read This Analysis Before Investing in Dogwood Therapeutics Inc (NASDAQ:DWTX) - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Dogwood Therapeutics (DWTX) Begins Phase 2b Trial for Halneuron - GuruFocus
Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance - GuruFocus
Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance with Equit - GuruFocus
Dogwood Therapeutics regains Nasdaq compliance By Investing.com - Investing.com South Africa
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of Compliance - marketscreener.com
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance - GlobeNewswire
Nasdaq Delisting Risk Eliminated: Dogwood Therapeutics Secures Future with $17.5M War Chest - Stock Titan
Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire
DWTX: Interim Data for Phase 2b Trial in 4Q25… - Yahoo Finance
Dogwood Therapeutics regains compliance with Nasdaq - MSN
Dogwood Therapeutics Announces Nasdaq Compliance Regained - Nasdaq
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire
Dogwood Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Dogwood Therapeutics, Inc. SEC 10-K Report - TradingView
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Dogwood Strengthens Balance Sheet with $24M Capital Actions as Halneuron Trial Progresses - Stock Titan
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain By Investing.com - Investing.com South Africa
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet… - Zacks Small Cap Research
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain - Marketscreener.com
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain - Investing.com
Dogwood Therapeutics Announces Dosing of First Patient in - GlobeNewswire
Revolutionary Non-Addictive Pain Treatment Enters Critical Phase 2b Trial for Cancer Patients - StockTitan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Dogwood Therapeutics announces pricing of $4.8 million offering - MSN
Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge -March 13, 2025 at 09:40 am EDT - Marketscreener.com
Dogwood Therapeutics secures $4.8 million in direct offering By Investing.com - Investing.com Australia
Dogwood Therapeutics secures $4.8 million in direct offering - Investing.com
Dogwood Therapeutics Secures $4.8 Million in Direct Offering to Advance Halneuron® Phase 2b Trial and Fund Operations Through Q1 2026 - Nasdaq
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 - GlobeNewswire
Dogwood Secures Critical Funding for Revolutionary Pain Treatment: What's Next for Halneuron? - StockTitan
Dogwood Therapeutics clears debt with equity swa By Investing.com - Investing.com Australia
Dogwood Therapeutics converts existing debt to equity -March 12, 2025 at 10:34 am EDT - Marketscreener.com
Dogwood Therapeutics Strengthens Balance Sheet with Debt Conversion - TipRanks
Dogwood Therapeutics clears debt with equity swa - Investing.com
Dogwood Therapeutics Announces Debt-to-Equity Exchange with CK Life Sciences, Strengthening Financial Position for Clinical Trials - Nasdaq
Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward - Financial Post
Dogwood Therapeutics, Inc. Announces Conversion of Existing - GlobeNewswire
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):